Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ERIC D WHITMAN

Allopathic & Osteopathic Physicians Surgery

NPI
1609840636
CMS profile
299135
Location
MORRISTOWN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$108,171.74

158 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 158 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ERIC D WHITMAN

NPI 1609840636 · CMS profile ID 299135

Allopathic & Osteopathic Physicians / Surgery

MORRISTOWN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 158 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1609840636?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ERIC D WHITMAN, NPI 1609840636, CMS profile ID 299135. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 158 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1609840636?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ERIC D WHITMAN, NPI 1609840636, CMS profile ID 299135. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 158 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1609840636?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ERIC D WHITMAN, NPI 1609840636, CMS profile ID 299135, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 158 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1609840636?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

158 matching records · $108,171.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 158 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 158.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Daiichi Sankyo Inc. $16.5505/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006422573 CMS
GlaxoSmithKline, LLC. $16.9705/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002906227 CMS
Karyopharm Therapeutics Inc. $18.8104/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056900011 CMS
Novartis Pharmaceuticals Corporation $17.5604/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993358405 CMS
E.R. Squibb & Sons, L.L.C. $5,929.0004/20/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016039799 CMS
Celgene Corporation $16.4804/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016039835 CMS
Regeneron Healthcare Solutions, Inc. $17.8004/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999538957 CMS
Seagen Inc. $16.4604/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995635319 CMS
Daiichi Sankyo Inc. $17.0004/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006349217 CMS
Regeneron Pharmaceuticals, Inc. $360.5004/06/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000041771 CMS
E.R. Squibb & Sons, L.L.C. $5,929.0004/05/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016039787 CMS
E.R. Squibb & Sons, L.L.C. $17.0004/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016039839 CMS
Mirati Therapeutics, Inc. $17.0903/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058006347 CMS
E.R. Squibb & Sons, L.L.C. $7,623.0003/29/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016039791 CMS
E.R. Squibb & Sons, L.L.C. $5,929.0003/29/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016039793 CMS
Merck Sharp & Dohme LLC $2,135.0003/29/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048343355 CMS
E.R. Squibb & Sons, L.L.C. $126.8903/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016039811 CMS
Novartis Pharmaceuticals Corporation $16.3603/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993358401 CMS
Daiichi Sankyo Inc. $17.0003/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006332709 CMS
E.R. Squibb & Sons, L.L.C. $1,137.7203/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016039771 CMS
E.R. Squibb & Sons, L.L.C. $58.2603/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016039779 CMS
E.R. Squibb & Sons, L.L.C. $890.3903/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016039775 CMS
E.R. Squibb & Sons, L.L.C. $124.9903/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016039783 CMS
E.R. Squibb & Sons, L.L.C. $5,929.0003/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016039955 CMS
E.R. Squibb & Sons, L.L.C. $124.9903/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016039801 CMS
E.R. Squibb & Sons, L.L.C. $1,112.9803/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016039807 CMS
E.R. Squibb & Sons, L.L.C. $766.7402/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016039943 CMS
E.R. Squibb & Sons, L.L.C. $122.4302/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016039959 CMS
Merck Sharp & Dohme LLC $19.6602/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048572877 CMS
Merck Sharp & Dohme LLC $13.9402/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048574661 CMS
Novartis Pharmaceuticals Corporation $15.8202/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993358393 CMS
Daiichi Sankyo Inc. $16.8002/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006388047 CMS
E.R. Squibb & Sons, L.L.C. $7,623.0002/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016039951 CMS
Daiichi Sankyo Inc. $16.7802/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006382901 CMS
Mirati Therapeutics, Inc. $11.7602/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058006345 CMS
Karyopharm Therapeutics Inc. $17.4102/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056900019 CMS
Seagen Inc. $16.3102/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995635171 CMS
E.R. Squibb & Sons, L.L.C. $2,964.0002/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016039947 CMS
E.R. Squibb & Sons, L.L.C. $17.0002/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016039743 CMS
Regeneron Pharmaceuticals, Inc. $721.0002/06/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000041721 CMS
Regeneron Pharmaceuticals, Inc. $4,326.0002/06/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000041731 CMS
Regeneron Pharmaceuticals, Inc. $4,326.0002/06/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000041741 CMS
Regeneron Pharmaceuticals, Inc. $85.0002/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000041751 CMS
Regeneron Pharmaceuticals, Inc. $85.0002/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000041761 CMS
GlaxoSmithKline, LLC. $16.8002/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002906283 CMS
GlaxoSmithKline, LLC. $16.3501/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002903890 CMS
E.R. Squibb & Sons, L.L.C. $1,063.5301/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016039935 CMS
E.R. Squibb & Sons, L.L.C. $106.6601/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016039939 CMS
Merck Sharp & Dohme LLC $16.9001/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048892175 CMS
Mirati Therapeutics, Inc. $16.4601/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058006341 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $269,304.93 228
PY2020 $105,285.48 77
PY2021 $89,779.72 87
PY2022 $132,338.68 154
PY2023 $108,171.74 158
PY2024 $70,484.40 116
PY2025 $72,164.79 88

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $291,406.34 36
PY2024 Principal investigator $575,230.51 36
PY2023 Principal investigator $425,311.74 60
PY2022 Principal investigator $270,055.09 36
PY2021 Principal investigator $1,172,150.90 47
PY2020 Principal investigator $504,808.31 52
PY2019 Principal investigator $184,609.53 34

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Iovance Biotherapeutics, Inc. $500.00 12/16/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
81990 No dispute reported 06/30/2026 1252498723
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,000.00 12/16/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
81990 No dispute reported 06/30/2026 1252498725
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,500.00 12/16/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
81990 No dispute reported 06/30/2026 1252498727
Principal investigator 1 Ascendis Pharma Endocrinology Inc $3,593.00 12/09/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
IL Believe No dispute reported 06/30/2026 1233998016
Principal investigator 1 BioNTech SE $675.00 11/06/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
BNT111 No dispute reported 06/30/2026 1249021751
Principal investigator 1 BioNTech SE $1,030.00 11/06/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
BNT111 No dispute reported 06/30/2026 1249021753
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 09/24/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220792513
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,000.00 09/23/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
81990 No dispute reported 06/30/2026 1252498081
Principal investigator 1 Iovance Biotherapeutics, Inc. $26,292.14 09/18/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
NCT02360579 No dispute reported 06/30/2026 1252498073
Principal investigator 1 Iovance Biotherapeutics, Inc. $7,000.00 09/18/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
NCT02360579 No dispute reported 06/30/2026 1252498075
Principal investigator 1 Iovance Biotherapeutics, Inc. $4,248.90 09/18/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
NCT02360579 No dispute reported 06/30/2026 1252498077
Principal investigator 1 Iovance Biotherapeutics, Inc. $500.00 09/16/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
81990 No dispute reported 06/30/2026 1252498083
Principal investigator 1 Merck Sharp & Dohme LLC $215,866.72 08/31/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical study of Adjuvant V940 mRNA-4157 Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma INTerpath-001 No dispute reported 06/30/2026 1232933284
Principal investigator 1 Ascendis Pharma Endocrinology Inc $3,141.00 08/13/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
IL Believe No dispute reported 06/30/2026 1233996653
Principal investigator 1 Iovance Biotherapeutics, Inc. $337.00 07/15/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
81990 No dispute reported 06/30/2026 1252498071
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,000.00 07/01/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
81990 No dispute reported 06/30/2026 1252498079
Principal investigator 1 BioNTech SE $675.00 06/19/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
BNT111-01 No dispute reported 06/30/2026 1249021637
Principal investigator 1 BioNTech SE $675.00 06/19/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
BNT111-01 No dispute reported 06/30/2026 1249021673
Principal investigator 1 Iovance Biotherapeutics, Inc. $500.00 06/17/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
81990 No dispute reported 06/30/2026 1252496793
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,354.00 04/29/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220792511
Principal investigator 1 BioNTech SE $675.00 04/17/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
BNT111-01 No dispute reported 06/30/2026 1249021635
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,500.00 04/17/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
81990 No dispute reported 06/30/2026 1252496789
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,000.00 04/17/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
81990 No dispute reported 06/30/2026 1252496791
Principal investigator 1 Ascendis Pharma Endocrinology Inc $3,141.00 04/11/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
IL Believe No dispute reported 06/30/2026 1233995321
Principal investigator 1 Iovance Biotherapeutics, Inc. $500.00 04/01/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
81990 No dispute reported 06/30/2026 1252496785
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,000.00 04/01/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
81990 No dispute reported 06/30/2026 1252496787
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,500.00 03/28/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220792509
Principal investigator 1 Iovance Biotherapeutics, Inc. $500.00 03/27/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
NCT02360579 No dispute reported 06/30/2026 1252496797
Principal investigator 1 Iovance Biotherapeutics, Inc. $400.00 03/27/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
NCT02360579 No dispute reported 06/30/2026 1252496799
Principal investigator 1 BioNTech SE $675.00 03/25/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
BNT111-01 No dispute reported 06/30/2026 1249021593
Principal investigator 1 BioNTech SE $338.00 03/25/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
BNT111-01 No dispute reported 06/30/2026 1249021595
Principal investigator 1 Iovance Biotherapeutics, Inc. $137.70 02/18/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
81990 No dispute reported 06/30/2026 1252496783
Principal investigator 1 Exelixis Inc. $6,146.88 02/10/2025 Covered Recipient Teaching Hospital
Overlook Medical Center
A Phase 3, Randomized, Double-blinded, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Radioiodine Refractory Defferentiated Thyroid Cancer who have Progressed after Prior VEGFR Targeted Therapy No dispute reported 06/30/2026 1222377406
Principal investigator 1 Iovance Biotherapeutics, Inc. $500.00 01/21/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
81990 No dispute reported 06/30/2026 1252496801
Principal investigator 1 Iovance Biotherapeutics, Inc. $400.00 01/16/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
NCT02360579 No dispute reported 06/30/2026 1252496795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $605.00 01/06/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184132822